ACP
Acuta Capital Partners Portfolio holdings
AUM
$71.6M
This Quarter Return
+56.19%
1 Year Return
+169.78%
3 Year Return
+1,553.75%
5 Year Return
+4,509.01%
10 Year Return
+155,159.98%
AUM
$178M
AUM Growth
+$178M
(+29%)
Cap. Flow
-$86.3M
Cap. Flow
% of AUM
-48.6%
Top 10 Holdings %
Top 10 Hldgs %
56.23%
Holding
55
New
11
Increased
13
Reduced
10
Closed
15
Top Buys
| 1 |
Tourmaline Bio
TRML
|
$6.07M |
| 2 |
Ocular Therapeutix
OCUL
|
$5.84M |
| 3 |
Sarepta Therapeutics
SRPT
|
$5.31M |
| 4 |
Mersana Therapeutics
MRSN
|
$5.26M |
| 5 |
Revolution Medicines
RVMD
|
$4.59M |
Top Sells
| 1 |
Praxis Precision Medicines
PRAX
|
$93.2M |
| 2 |
Apellis Pharmaceuticals
APLS
|
$10.1M |
| 3 |
Ventyx Biosciences
VTYX
|
$7.13M |
| 4 |
Syndax Pharmaceuticals
SNDX
|
$4.31M |
| 5 |
Alkermes
ALKS
|
$3.54M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
RYZB
1
DELISTED
RayzeBio, Inc. Common Stock
RYZB
| $23.5M | 13.23% | 378,069 +33,498 | +10% | +$2.08M |
|
|
CBAY
2
DELISTED
Cymabay Therapeutics
CBAY
| $11.6M | 6.54% | 492,155 +74,155 | +18% | +$1.75M |
|
3
Rocket Pharmaceuticals
RCKT
$354M
| $11M | 6.17% | 366,015 +4,015 | +1% | +$120K |
|
4
Kura Oncology
KURA
$686M
| $10.1M | 5.68% | 701,349 -744 | -0.1% | -$10.7K |
|
5
EyePoint Pharmaceuticals
EYPT
$797M
| $9.82M | 5.53% | 425,128 +125,000 | +42% | +$2.89M |
|
6
Vaxcyte
PCVX
$4B
| $7.37M | 4.15% | 117,373 -3,649 | -3% | -$229K |
|
|
7
Sarepta Therapeutics
SRPT
$1.78B
| $6.81M | 3.83% | 70,600 +55,100 | +355% | +$5.31M |
|
|
8
Praxis Precision Medicines
PRAX
$958M
| $6.68M | 3.76% | 299,636 -4,185,364 | -93% | -$93.2M |
|
9
Disc Medicine
IRON
$2.07B
| $6.67M | 3.76% | 115,500 -22,698 | -16% | -$1.31M |
|
10
Taysha Gene Therapies
TSHA
$797M
| $6.35M | 3.58% | 3,589,333 -238,593 | -6% | -$422K |
|
11
Viridian Therapeutics
VRDN
$1.5B
| $6.13M | 3.45% | 281,500 +57,161 | +25% | +$1.24M |
|
|
12
Tourmaline Bio
TRML
$601M
| $6.07M | 3.42% | +231,882 | New | +$6.07M |
|
|
13
Ocular Therapeutix
OCUL
$2.12B
| $5.84M | 3.29% | +1,310,000 | New | +$5.84M |
|
|
14
Mersana Therapeutics
MRSN
$36.5M
| $5.49M | 3.09% | 2,368,000 +2,268,393 | +2,277% | +$5.26M |
|
15
HilleVax
HLVX
$105M
| $5.21M | 2.93% | 324,600 +54,281 | +20% | +$871K |
|
16
Immunovant
IMVT
$2.56B
| $5.03M | 2.83% | 119,489 -9,511 | -7% | -$401K |
|
|
17
Revolution Medicines
RVMD
$7.1B
| $4.59M | 2.58% | +160,000 | New | +$4.59M |
|
|
18
Apellis Pharmaceuticals
APLS
$3.48B
| $4.56M | 2.56% | 76,100 -168,384 | -69% | -$10.1M |
|
19
Arcellx
ACLX
$3.85B
| $4.27M | 2.41% | +77,000 | New | +$4.27M |
|
|
WHWK
20
Whitehawk Therapeutics, Inc. Common Stock
WHWK
$84.8M
| $3.74M | 2.1% | 1,849,402 | – | – |
|
21
Terns Pharmaceuticals
TERN
$609M
| $3.6M | 2.03% | 555,260 | – | – |
|
22
Crinetics Pharmaceuticals
CRNX
$2.92B
| $3.11M | 1.75% | 87,500 -6,500 | -7% | -$231K |
|
23
Celldex Therapeutics
CLDX
$1.47B
| $2.75M | 1.55% | 69,400 -52,941 | -43% | -$2.1M |
|
24
AN2 Therapeutics
ANTX
$30.1M
| $2.7M | 1.52% | 132,000 +118,700 | +892% | +$2.43M |
|
25
Dyne Therapeutics
DYN
$1.92B
| $1.97M | 1.11% | 147,836 +1,336 | +0.9% | +$17.8K |
|